Pubblicazioni

Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis

2019 - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Ferella, L.; Limoncin, E.; Vittorini, F.; Chalaszczyk, A.; Sorce, C.; Grimaldi, G.; Franzese, P.; Ruggieri, V.; Varrassi, E.; Di Staso, M.; Gimenez De Lorenzo, R.; Marampon, F.; Tombolini, V.; Masciocchi, C.; Gravina, G. L.

Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3Â Gy/fraction)

2019 - LA RADIOLOGIA MEDICA

Valeriani, M.; Marinelli, L.; Nicosia, L.; Reverberi, C.; De Sanctis, V.; Mollo, D.; Osti, M. F.

Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule

2019 - LA RADIOLOGIA MEDICA

Valeriani, M.; Marinelli, L.; Reverberi, C.; De Sanctis, V.; Mollo, D.; Nicosia, L.; Osti, M. F.